EUR 1.41
(-0.71%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 18 Thousand USD | -99.9% |
2022 | 17.39 Million USD | -53.82% |
2021 | 37.67 Million USD | 0.0% |
2020 | 37.67 Million USD | 891.94% |
2019 | 3.79 Million USD | -61.99% |
2018 | 9.99 Million USD | -55.72% |
2017 | 22.56 Million USD | -44.82% |
2016 | 40.89 Million USD | -21.86% |
2015 | 52.33 Million USD | 131.5% |
2014 | 22.6 Million USD | 2.91% |
2013 | 21.96 Million USD | -14.8% |
2012 | 25.78 Million USD | 47.61% |
2011 | 17.46 Million USD | -8.34% |
2010 | 19.05 Million USD | 27.11% |
2009 | 14.99 Million USD | 13.35% |
2008 | 13.22 Million USD | 404.03% |
2007 | 2.62 Million USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 4.52 Million USD | 3803.45% |
2024 Q2 | 9.5 Million USD | 109.87% |
2023 Q3 | -26 Thousand USD | -121.14% |
2023 FY | 18 Thousand USD | -99.9% |
2023 Q4 | 116 Thousand USD | 546.15% |
2023 Q1 | -195 Thousand USD | -101.27% |
2023 Q2 | 123 Thousand USD | 163.08% |
2022 Q4 | 15.33 Million USD | 10322.67% |
2022 Q1 | 1.31 Million USD | 126.27% |
2022 FY | 17.39 Million USD | -53.82% |
2022 Q2 | 1.01 Million USD | -22.33% |
2022 Q3 | -150 Thousand USD | -114.72% |
2021 Q3 | -902 Thousand USD | -55.79% |
2021 Q2 | -579 Thousand USD | -103.32% |
2021 Q4 | -4.99 Million USD | -453.77% |
2021 FY | 37.67 Million USD | 0.0% |
2021 Q1 | 17.45 Million USD | 449.47% |
2020 FY | 37.67 Million USD | 891.94% |
2020 Q1 | 45.52 Million USD | 3804.56% |
2020 Q2 | -2.92 Million USD | -106.43% |
2020 Q3 | -1.64 Million USD | 43.97% |
2020 Q4 | -4.99 Million USD | -204.57% |
2019 Q2 | 337 Thousand USD | -24.94% |
2019 Q3 | 4.23 Million USD | 1155.79% |
2019 FY | 3.79 Million USD | -61.99% |
2019 Q1 | 449 Thousand USD | 81.05% |
2019 Q4 | -1.22 Million USD | -129.04% |
2018 FY | 9.99 Million USD | -55.72% |
2018 Q4 | 248 Thousand USD | 570.27% |
2018 Q3 | 37 Thousand USD | -99.18% |
2018 Q2 | 4.49 Million USD | -17.78% |
2018 Q1 | 5.46 Million USD | 12.78% |
2017 Q3 | 5.55 Million USD | -9.94% |
2017 Q4 | 4.84 Million USD | -12.8% |
2017 FY | 22.56 Million USD | -44.82% |
2017 Q2 | 6.16 Million USD | 0.28% |
2017 Q1 | 6.14 Million USD | -16.81% |
2016 Q2 | 17.27 Million USD | 132.93% |
2016 Q4 | 7.39 Million USD | -32.63% |
2016 Q3 | 10.97 Million USD | -36.5% |
2016 FY | 40.89 Million USD | -21.86% |
2016 Q1 | 7.41 Million USD | -73.57% |
2015 Q2 | 7.77 Million USD | -10.21% |
2015 FY | 52.33 Million USD | 131.5% |
2015 Q1 | 8.66 Million USD | -1.59% |
2015 Q4 | 28.06 Million USD | 243.26% |
2015 Q3 | 8.17 Million USD | 5.09% |
2014 Q1 | 6.11 Million USD | 19.64% |
2014 FY | 22.6 Million USD | 2.91% |
2014 Q4 | 8.8 Million USD | -4.09% |
2014 Q3 | 9.18 Million USD | 51.2% |
2014 Q2 | 6.07 Million USD | -0.64% |
2013 Q3 | 5.01 Million USD | 62.12% |
2013 Q4 | 5.1 Million USD | 1.75% |
2013 FY | 21.96 Million USD | -14.8% |
2013 Q1 | 3.05 Million USD | 72.56% |
2013 Q2 | 3.09 Million USD | 1.46% |
2012 Q4 | 1.76 Million USD | -77.95% |
2012 FY | 25.78 Million USD | 47.61% |
2012 Q3 | 8.02 Million USD | 0.0% |
2011 FY | 17.46 Million USD | -8.34% |
2010 FY | 19.05 Million USD | 27.11% |
2009 FY | 14.99 Million USD | 13.35% |
2008 FY | 13.22 Million USD | 404.03% |
2007 FY | 2.62 Million USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
ABIONYX Pharma SA | 618 Thousand EUR | 97.087% |
ABIVAX Société Anonyme | 3.91 Million EUR | 99.54% |
Adocia SA | 1.38 Million EUR | 98.7% |
Aelis Farma SA | 12.35 Million EUR | 99.854% |
Biophytis S.A. | -803 Thousand EUR | 102.242% |
Advicenne S.A. | 1.42 Million EUR | 98.738% |
genOway Société anonyme | 20.1 Million EUR | 99.91% |
IntegraGen SA | 5.01 Million EUR | 99.641% |
Medesis Pharma S.A. | -2.66 Million EUR | 100.675% |
Neovacs S.A. | 29.31 Thousand EUR | 38.596% |
NFL Biosciences SA | -56.06 Thousand EUR | 132.106% |
Plant Advanced Technologies SA | 2.15 Million EUR | 99.164% |
Quantum Genomics Société Anonyme | -1.41 Million EUR | 101.268% |
Sensorion SA | 3.78 Million EUR | 99.525% |
Theranexus Société Anonyme | -4.63 Million EUR | 100.388% |
TME Pharma N.V. | -127 Thousand EUR | 114.173% |
Valbiotis SA | 2.66 Million EUR | 99.325% |
TheraVet SA | -530.79 Thousand EUR | 103.391% |
Valerio Therapeutics Société anonyme | 1.26 Million EUR | 98.579% |
DBV Technologies S.A. | 4.15 Million EUR | 99.567% |
Genfit S.A. | 28.22 Million EUR | 99.936% |
GeNeuro SA | -293.8 Thousand EUR | 106.127% |
Innate Pharma S.A. | -4.12 Million EUR | 100.437% |
Inventiva S.A. | 17.5 Million EUR | 99.897% |
MaaT Pharma SA | 1.65 Million EUR | 98.912% |
MedinCell S.A. | 9.28 Million EUR | 99.806% |
Nanobiotix S.A. | 36.2 Million EUR | 99.95% |
OSE Immunotherapeutics SA | 2.22 Million EUR | 99.192% |
Poxel S.A. | 1000.00 EUR | -1700.0% |
GenSight Biologics S.A. | 3 Million EUR | 99.4% |
Transgene SA | -28.4 Million EUR | 100.063% |
Valneva SE | 52.83 Million EUR | 99.966% |